This year, GAAPP has partnered with Aspergillosis Trust UK to develop an international awareness campaign for World Aspergillosis Day (February 3, 2025).

  • Global Aspergillosis Cases: An estimated 3 million people globally are affected by chronic pulmonary aspergillosis (CPA). (1)
  • Invasive Aspergillosis (IA): It occurs in approximately 1-2% of patients with hematological malignancies or undergoing bone marrow transplantation and in up to 20% of patients with high-risk conditions in intensive care units (ICUs). (2)
  • Allergic Bronchopulmonary Aspergillosis (ABPA): ABPA affects 1-3% of asthma patients globally and 7-15% of patients with cystic fibrosis. This translates to approximately 4.8 million individuals worldwide. (1-2)

What is Aspergillosis?

The term Aspergillosis covers a range of conditions. These are lifelong, fungal lung infections which are due to the fungus Aspergillus. These cause allergic reactions, making it difficult to breathe. They may cause lung damage (erosion of lung tissue/cavities) instead or as well. This causes loss of lung function and difficulty breathing. Aspergillosis often affects people with asthma, especially those with severe asthma. It seems to make asthma worse. Learn more

World Aspergillosis Day 2025

This year, we created a series of images and Reels for social media to raise global awareness of Aspergillosis among the general public. To maximize their impact, GAAPP collaborated with 15 of its member organizations specializing in respiratory conditions often comorbid with Aspergillosis. This partnership ensured that the awareness materials were tailored to local communities, translated into their native languages, and adapted to their cultural contexts.

  • 🟣 Join the movement! 🟣 Wear purple, share your support for #WorldAspergillosisDay. Let’s unite to raise awareness in this campaign powered by Aspergillosis Trust. Your voice matters! #WearPurpleForAspergillosis #ATawareness #SupportedByGAAPP
  • 🔬 Time for Change! We need new treatments for Aspergillosis. Support research and innovation to combat resistance. An initiative powered by Aspergillosis Trust. #SupportedByGAAPP #WorldAspergillosisDay #FightAspergillosis
  • 🚨 Early Diagnosis Saves Lives! Understanding Aspergillosis early can change outcomes. Let’s advocate for timely diagnosis this #WorldAspergillosisDay. Brought to you by Aspergillosis Trust. #EarlyDetection #PatientCare #SupportedByGAAPP
  • 💡 Educate & Empower! This upcoming #WorldAspergillosisDay, Aspergillosis Trust, with GAAPP’s support, would like to invite you to spread knowledge about Aspergillosis to healthcare professionals and patients. Knowledge is power! #AspergillosisEducation #HealthcareAwareness #SupportedByGAAPP
  • 🌍 Global Care for Aspergillosis! Today on #WorldAspergillosisDay, let’s ensure access to specialist care and support for all. Together, we can make a difference! Thank you for joining Aspergillosis Trust on this campaign! #GlobalHealth #AspergillosisSupport #SupportedByGAAPP

Join GAAPP and Aspergillosis Trust Joint Awareness Day Camp

Do you want to join us in promoting the assets in your own language? You can download the asset on this folder and you can contact us if your language is missing.

Download the assets

About Aspergillos Trust

Aspergillosis Trust is a patient advocacy group. It is run by patients and carers in the UK and the EU. It is a rare debilitating and sometimes deadly infection. It can attack people of any age. Aspergillosis Trust (AT) also raise funds for desperately needed research. They are a patient-led group, committed to working with anyone who has an interest in supporting our work or learning from our experiences.

The Aspergillosis Trust is a leading organization dedicated to supporting patients, raising awareness, and creating educational content, as well as contributing to ongoing research (as of 2025). We encourage you to learn more about their work and explore their extensive library of multilingual resources.

Explore the Aspergillosis Trust Website

Registry

A CPAnet consensus statement on research priorities for chronic pulmonary aspergillosis: a neglected fungal infection that requires attention

For educational purposes only. Contact your HCP to join.

Key References:

  1. World Health Organization (WHO)
    • Reports on fungal infections, particularly in the context of respiratory diseases and global health.
  2. Global Action for Fungal Infections (GAFFI)
    • Regularly publishes estimates and updates on the global burden of fungal diseases, including aspergillosis.
    • Website: https://gaffi.org
  3. Centers for Disease Control and Prevention (CDC)
    • Provides detailed information on the epidemiology of aspergillosis, including data on invasive and chronic forms.
    • Website: https://cdc.gov
  4. Research Papers and Reviews:
    • Denning DW, et al. (2017): “The burden of chronic pulmonary aspergillosis as a sequel to pulmonary tuberculosis in Africa.” European Respiratory Journal.
    • Denning DW, et al. (2013): “Global burden of allergic bronchopulmonary aspergillosis with asthma and its complication, chronic pulmonary aspergillosis, in adults.” Medical Mycology.
  5. National Institutes of Health (NIH)
    • Comprehensive reviews on the clinical and epidemiological aspects of aspergillosis.
  6. Scientific Journals and Articles:
    • The Lancet Respiratory Medicine: Publishes studies on fungal infections, including aspergillosis prevalence and outcomes.
    • Journal of Fungi: Articles on regional and global trends in fungal diseases.
  7. COVID-19-Associated Pulmonary Aspergillosis (CAPA):
    • Koehler P, et al. (2021): “COVID-19-associated pulmonary aspergillosis.” The Lancet Microbe.
  8. Fungal Infection Trust (FIT)
    • Educational and epidemiological resources about fungal infections like aspergillosis.